Hydroxychloroquine
Hydroxychloroquine, Plaquenil, Sovuna (hydroxychloroquine) is a small molecule pharmaceutical. Hydroxychloroquine was first approved as Plaquenil on 1982-01-01. It is used to treat malaria, photosensitivity disorders, porphyria cutanea tarda, rheumatic diseases, and rheumatoid arthritis amongst others in the USA. The pharmaceutical is active against toll-like receptor 9 and toll-like receptor 7.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Plaquenil, Sovuna (generic drugs available since 1994-09-30)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Hydroxychloroquine sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PLAQUENIL | Concordia Laboratories | N-009768 RX | 1982-01-01 | 1 products, RLD, RS |
| SOVUNA | Novitium Pharma | N-214581 RX | 2022-01-14 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| hydroxychloroquine sulfate | ANDA | 2024-01-09 |
| hydroxychloroquinesulfate | ANDA | 2018-07-06 |
| plaquenil | New Drug Application | 2023-12-20 |
| sovuna | New Drug Application | 2023-09-19 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
571 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | 11 | 70 | 90 | 23 | 39 | 207 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | 8 | 18 | 19 | 13 | 56 |
| Sars-cov-2 | D000086402 | — | — | 3 | 16 | 12 | 2 | 3 | 31 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | 1 | 8 | 13 | 3 | 7 | 28 |
| Systemic lupus erythematosus | D008180 | HP_0002725 | M32 | 2 | 4 | 5 | 3 | 8 | 21 |
| Severe acute respiratory syndrome-related coronavirus | D045473 | NCBITaxon_227859 | — | — | 5 | 8 | 1 | 1 | 14 |
| Pneumonia | D011014 | EFO_0003106 | — | — | 2 | 2 | 1 | 5 | 10 |
| Antiphospholipid syndrome | D016736 | EFO_0002689 | D68.61 | — | 2 | 2 | 1 | 3 | 8 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | 2 | — | 2 | — | 4 |
| Spontaneous abortion | D000022 | EFO_1001255 | O00.1 | — | 1 | 1 | 1 | — | 3 |
Show 24 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronavirus | D017934 | — | — | — | 5 | 8 | — | 4 | 17 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | 1 | 4 | 7 | — | 1 | 11 |
| Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | 5 | 3 | — | 4 | 10 |
| Severe acute respiratory syndrome | D045169 | EFO_0000694 | J12.81 | 1 | 1 | 5 | — | 1 | 7 |
| Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | — | 2 | 2 | — | 3 | 6 |
| Pregnancy rate | D018873 | — | — | 1 | — | 1 | — | 3 | 5 |
| Virus diseases | D014777 | — | B34 | — | 2 | 2 | — | — | 4 |
| Lupus nephritis | D008181 | EFO_0005761 | — | — | 1 | 2 | — | 1 | 4 |
| Respiratory tract infections | D012141 | — | J06.9 | — | — | 3 | — | — | 3 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | 1 | 3 | — | — | 3 |
Show 21 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 6 | 11 | — | — | — | 15 |
| Neoplasms | D009369 | — | C80 | 10 | 4 | — | — | — | 13 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 5 | 8 | — | — | — | 10 |
| Prostatic neoplasms | D011471 | — | C61 | 4 | 6 | — | — | — | 8 |
| Non-small-cell lung carcinoma | D002289 | — | — | 3 | 5 | — | — | — | 6 |
| Colorectal neoplasms | D015179 | — | — | 2 | 4 | — | — | — | 6 |
| Melanoma | D008545 | — | — | 4 | 3 | — | — | — | 5 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 4 | 2 | — | — | — | 4 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | 2 | 2 | — | — | — | 3 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | 3 | — | — | — | 3 |
Show 59 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 2 | — | — | — | — | 2 |
| Rheumatic diseases | D012216 | — | M79.0 | 1 | — | — | — | 1 | 2 |
| Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Lymphangioleiomyomatosis | D018192 | — | J84.81 | 1 | — | — | — | — | 1 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 1 | — | — | — | — | 1 |
| Muscle cramp | D009120 | HP_0003394 | — | 1 | — | — | — | — | 1 |
| Immunosuppression therapy | D007165 | — | — | 1 | — | — | — | — | 1 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 1 | — | — | — | — | 1 |
| Cutaneous lupus erythematosus | D008178 | EFO_0003834 | L93.1 | 1 | — | — | — | — | 1 |
Show 3 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diarrhea | D003967 | HP_0002014 | R19.7 | — | — | — | — | 2 | 2 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | — | — | — | 2 | 2 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | — | — | 2 | 2 |
| Hashimoto disease | D050031 | EFO_0003779 | E06.3 | — | — | — | — | 2 | 2 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | — | — | — | 1 | 1 |
| Immunotherapy | D007167 | — | — | — | — | — | — | 1 | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | — | — | 1 | 1 |
| Prevalence | D015995 | — | — | — | — | — | — | 1 | 1 |
| Risk factors | D012307 | EFO_0003919 | — | — | — | — | — | 1 | 1 |
| Undifferentiated connective tissue diseases | D000074079 | — | — | — | — | — | — | 1 | 1 |
Show 13 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Hydroxychloroquine |
| INN | hydroxychloroquine |
| Description | Hydroxychloroquine is an aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions. It has a role as an antimalarial, an antirheumatic drug, a dermatologic drug and an anticoronaviral agent. It is an aminoquinoline, an organochlorine compound, a primary alcohol, a secondary amino compound and a tertiary amino compound. It is functionally related to a chloroquine. It is a conjugate base of a hydroxychloroquine(2+). |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12 |
Identifiers
| PDB | — |
| CAS-ID | 118-42-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1535 |
| ChEBI ID | 5801 |
| PubChem CID | 3652 |
| DrugBank | DB01611 |
| UNII ID | 4QWG6N8QKH (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Hydroxychloroquine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 47,583 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
50,071 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use